144 related articles for article (PubMed ID: 16257382)
21. Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.
Collins SA; Shah AH; Ostertag D; Kasahara N; Jolly DJ
Expert Opin Biol Ther; 2021 Sep; 21(9):1199-1214. PubMed ID: 33724117
[TBL] [Abstract][Full Text] [Related]
22. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in the research of suicide gene therapy for malignant glioma.
Tamura R; Miyoshi H; Yoshida K; Okano H; Toda M
Neurosurg Rev; 2021 Feb; 44(1):29-49. PubMed ID: 31781985
[TBL] [Abstract][Full Text] [Related]
24. Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models.
Lee M; Kim YS; Lee K; Kang M; Shin H; Oh JW; Koo H; Kim D; Kim Y; Kong DS; Nam DH; Lee HW
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370279
[TBL] [Abstract][Full Text] [Related]
25. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
26. Dual-vector prodrug activator gene therapy using retroviral replicating vectors.
Kubo S; Takagi-Kimura M; Tagawa M; Kasahara N
Cancer Gene Ther; 2019 May; 26(5-6):128-135. PubMed ID: 30348946
[TBL] [Abstract][Full Text] [Related]
27. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
Chiocca EA; Nassiri F; Wang J; Peruzzi P; Zadeh G
Neuro Oncol; 2019 Jan; 21(1):14-25. PubMed ID: 30346600
[TBL] [Abstract][Full Text] [Related]
28. Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.
Kubo S; Takagi-Kimura M; Kasahara N
Cancer Gene Ther; 2019 Feb; 26(1-2):41-47. PubMed ID: 30042500
[TBL] [Abstract][Full Text] [Related]
29. Gene Delivery in Neuro-Oncology.
Dixit K; Kumthekar P
Curr Oncol Rep; 2017 Sep; 19(11):69. PubMed ID: 28866732
[TBL] [Abstract][Full Text] [Related]
30. Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics.
Chandrawati R; Olesen MTJ; Marini TCC; Bisra G; Guex AG; de Oliveira MG; Zelikin AN; Stevens MM
Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28699219
[TBL] [Abstract][Full Text] [Related]
31. Nanotherapeutic systems for local treatment of brain tumors.
Chakroun RW; Zhang P; Lin R; Schiapparelli P; Quinones-Hinojosa A; Cui H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Jan; 10(1):. PubMed ID: 28544801
[TBL] [Abstract][Full Text] [Related]
32. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Mitchell LA; Lopez Espinoza F; Mendoza D; Kato Y; Inagaki A; Hiraoka K; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2017 Jul; 19(7):930-939. PubMed ID: 28387849
[TBL] [Abstract][Full Text] [Related]
33. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Hiraoka K; Inagaki A; Kato Y; Huang TT; Mitchell LA; Kamijima S; Takahashi M; Matsumoto H; Hacke K; Kruse CA; Ostertag D; Robbins JM; Gruber HE; Jolly DJ; Kasahara N
Neuro Oncol; 2017 Jul; 19(7):918-929. PubMed ID: 28387831
[TBL] [Abstract][Full Text] [Related]
34. Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma.
Shneor D; Folberg R; Pe'er J; Honigman A; Frenkel S
Cancer Gene Ther; 2017 Feb; 24(2):64-74. PubMed ID: 27934882
[TBL] [Abstract][Full Text] [Related]
35. EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.
Saha D; Ahmed SS; Rabkin SD
Drugs Future; 2015; 40(11):739-749. PubMed ID: 26855472
[TBL] [Abstract][Full Text] [Related]
36. Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.
Burnett R; Ibañez CE; Pettersson PL; Chen CI; Parab S; Huang T; Robbins J; Bankiewicz K; Aghi M; Logg C; Kasahara N; Pertschuk D; Gruber HE; Jolly DJ
Mol Ther Methods Clin Dev; 2014; 1():14024. PubMed ID: 26015967
[TBL] [Abstract][Full Text] [Related]
37. Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes.
Erickson KL; Hickey MJ; Kato Y; Malone CC; Owens GC; Prins RM; Liau LM; Kasahara N; Kruse CA
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741775
[TBL] [Abstract][Full Text] [Related]
38. Brain tumors: Special characters for research and banking.
Kheirollahi M; Dashti S; Khalaj Z; Nazemroaia F; Mahzouni P
Adv Biomed Res; 2015; 4():4. PubMed ID: 25625110
[TBL] [Abstract][Full Text] [Related]
39. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
40. Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors.
Lai YH; Lin CC; Chen SH; Tai CK
Gene Ther; 2015 Feb; 22(2):155-62. PubMed ID: 25354682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
